Hearts and Minds Investments Ltd (AU:HM1) has released an update.
Hearts and Minds Investments Ltd reported a strong performance with their portfolio up 4.6% in July, outpacing the MSCI World Index, and delivering a 10% annualized pre-tax investment return since inception in November 2018. The company highlighted a fully franked dividend yield of 5.1% and a post-tax NTA of $3.15, while also announcing significant developments for Telix Pharmaceuticals, including an upgraded revenue forecast and progress with FDA applications. Despite market concerns over AI overinvestment and the potential for a tougher economic soft landing, the investment firm remains ahead with cumulative medical research funding reaching $48.9 million.
For further insights into AU:HM1 stock, check out TipRanks’ Stock Analysis page.